Skip to main content
ALZN
NASDAQ Life Sciences

Alzamend Cuts Ault Lending Preferred Deal to $10M, Adds Ratchet and Registration Penalties

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$1.35
Mkt Cap
$6.515M
52W Low
$0.84
52W High
$2.56
52W Position info
61% above low
Off High info
47% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ALZN sits 61% above its 52-week low of $0.84 on light trading volume (0.2× avg).

Summary

Alzamend amended its Ault Lending Series D preferred deal down from $25 million to $10 million, leaving only a $2.5 million second tranche after the $7.5 million already funded. The restated terms add a conversion-price ratchet, registration liquidated damages and a requirement to suspend the at-the-market offering.


Key Events · Financing and Capital Events · ALZN

  • Preferred Deal Cut to $10 Million

    The amended and restated securities purchase agreement with Ault Lending reduces the total from $25 million to $10 million; the 15 subsequent $1 million monthly tranches are eliminated, leaving only the $7.5 million already funded plus a $2.5 million second tranche.

  • Conversion Terms and Full Ratchet

    Each $1,050 stated-value preferred share converts at the greater of a $0.2668 floor or 80% of the lowest five-day closing bid, capped at $2.00, and the price ratchets down to any lower future issuance price (never below the floor). Conversion is blocked above 4.99% ownership and above 19.99% of shares outstanding until stockholder approval.

  • Registration Deadline and Penalties

    The company must file a resale registration statement by November 17, 2026 and have it effective within 60 days (90 days on full SEC review), or pay 2% of stated value per month in liquidated damages, capped at 15%.

  • ATM Must Be Suspended

    Closing the $2.5 million second tranche requires the company to suspend its existing at-the-market offering and have the resale registration statement effective, with a Termination Date of December 31, 2026.


Analysis · ALZN · Life Sciences

The $25 million preferred line with Ault Lending is now a $10 million deal: $7.5 million already closed on July 31, 2026, and only a $2.5 million second tranche remains, with the 15 monthly $1 million follow-on purchases eliminated. That removes roughly $15 million of previously contemplated funding from a company that reported going-concern doubt in its September 10, 2026 10-Q, so the runway question gets tighter, not looser. The terms are also more punitive than a plain preferred: conversion at the greater of $0.2668 or 80% of the lowest five-day closing bid (capped at $2.00), a full ratchet down to any lower future issuance price, a 2% monthly liquidated-damages clock if the resale registration is not filed by November 17, 2026 and effective within 60 days, and a requirement to suspend the existing at-the-market program before the second tranche can close. Ault Lending also locks in a most-favored-nation clause, a three-year right of first refusal, a 33.33% participation right and the option to buy another $10 million. Conversion is capped at 4.99% ownership and at 19.99% of shares outstanding until stockholders approve, with a special meeting targeted within 75 days of November 10, 2026.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALZN was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $0.84 to $2.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALZN - Latest Insights

ALZN
Sep 10, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $1.33 info
Change: -$0.370 (-22%) info
Market Cap: $6.418M info
ALZN
Aug 28, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $1.33 info
Change: -$0.330 (-20%) info
Market Cap: $6.418M info
ALZN
Aug 21, 2026, 4:30 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.33 info
Change: -$0.170 (-11%) info
Market Cap: $6.418M info
ALZN
Aug 03, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $1.33 info
Change: -$0.020 (-1%) info
Market Cap: $6.418M info
ALZN
Jul 22, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $1.33 info
Change: -$0.020 (-1%) info
Market Cap: $6.418M info